Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGN Allergan	$193.02	$190.89	$114.27 ▼ $202.21	$63.50B	1.2	4.01 million shs	12.44 million shs
AZN AstraZeneca	$74.42 -0.8%	$69.81	$61.24 ▼ $87.68	$230.80B	0.38	5.20 million shs	3.13 million shs
LLY Eli Lilly and Company	$818.56 +0.8%	$775.43	$677.09 ▼ $972.53	$775.78B	0.41	3.66 million shs	2.75 million shs
NVO Novo Nordisk A/S	$79.90 -1.4%	$67.30	$57.00 ▼ $148.15	$363.71B	0.66	7.04 million shs	7.47 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGN Allergan	0.00%	0.00%	0.00%	0.00%	0.00%
AZN AstraZeneca	0.00%	+2.11%	+9.51%	-4.10%	-7.06%
LLY Eli Lilly and Company	0.00%	+6.31%	+11.76%	+0.62%	-5.74%
NVO Novo Nordisk A/S	0.00%	+6.97%	+20.94%	+3.47%	-44.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGN Allergan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AZN AstraZeneca	2.8684 of 5 stars	2.6	5.0	1.7	0.0	2.8	0.0	1.3
LLY Eli Lilly and Company	4.8357 of 5 stars	3.4	3.0	3.3	4.0	3.4	1.7	1.9
NVO Novo Nordisk A/S	4.6218 of 5 stars	4.1	3.0	2.5	0.0	2.2	0.0	4.4

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGN Allergan	0.00	N/A	N/A	N/A
AZN AstraZeneca	3.13	Buy	$85.00	14.22% Upside
LLY Eli Lilly and Company	2.76	Moderate Buy	$1,011.37	23.55% Upside
NVO Novo Nordisk A/S	2.27	Hold	$112.00	40.17% Upside

Current Analyst Ratings Breakdown

Latest AZN, AGN, LLY, and NVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	LLY Eli Lilly and Company	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
5/23/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/2/2025	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$1,100.00 ➝ $1,050.00
5/1/2025	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/1/2025	LLY Eli Lilly and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/1/2025	LLY Eli Lilly and Company	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/28/2025	LLY Eli Lilly and Company	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Reduce	$1,150.00 ➝ $700.00
4/28/2025	LLY Eli Lilly and Company	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Moderate Sell
4/28/2025	NVO Novo Nordisk A/S	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/25/2025	NVO Novo Nordisk A/S	Dbs Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sell
4/22/2025	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$975.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGN Allergan	$16.09B	3.95	$36.70 per share	5.26	$177.28 per share	1.09
AZN AstraZeneca	$54.98B	4.20	$6.31 per share	11.79	$13.18 per share	5.65
LLY Eli Lilly and Company	$49.00B	15.83	$13.34 per share	61.34	$15.05 per share	54.39
NVO Novo Nordisk A/S	$303.14B	1.18	$3.70 per share	21.57	$4.64 per share	17.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGN Allergan	-$5.27B	$17.64	N/A	10.65	1.63	-15.44%	8.46%	5.31%	N/A
AZN AstraZeneca	$7.04B	$2.49	32.93	14.88	1.42	13.01%	32.23%	12.31%	7/24/2025 (Estimated)
LLY Eli Lilly and Company	$10.59B	$12.29	69.90	26.30	1.40	23.51%	85.24%	16.19%	8/7/2025 (Estimated)
NVO Novo Nordisk A/S	$14.64B	$3.38	24.29	17.15	0.90	34.81%	84.68%	26.29%	8/6/2025 (Estimated)

Latest AZN, AGN, LLY, and NVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	NVO Novo Nordisk A/S	$0.92	$0.92	N/A	$0.92	N/A	$11.87 billion
5/1/2025	Q1 2025	LLY Eli Lilly and Company	$4.64	$3.34	-$1.30	$3.06	$12.77 billion	$12.73 billion
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGN Allergan	$2.96	1.53%	N/A	16.78%	N/A
AZN AstraZeneca	$2.06	2.77%	N/A	82.73%	N/A
LLY Eli Lilly and Company	$6.00	0.73%	N/A	48.82%	11 Years
NVO Novo Nordisk A/S	$1.63	2.04%	N/A	48.22%	N/A

Latest AZN, AGN, LLY, and NVO Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/5/2025	LLY Eli Lilly and Company	quarterly	$1.50	0.73%	5/16/2025	5/16/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGN Allergan	0.31	1.01	0.84
AZN AstraZeneca	0.65	0.93	0.74
LLY Eli Lilly and Company	2.00	1.15	0.97
NVO Novo Nordisk A/S	0.62	0.74	0.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGN Allergan	83.91%
AZN AstraZeneca	20.35%
LLY Eli Lilly and Company	82.53%
NVO Novo Nordisk A/S	11.54%

Insider Ownership

Company	Insider Ownership
AGN Allergan	0.08%
AZN AstraZeneca	N/A
LLY Eli Lilly and Company	0.14%
NVO Novo Nordisk A/S	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGN Allergan	17,400	329.00 million	N/A	Optionable
AZN AstraZeneca	83,500	3.10 billion	N/A	Optionable
LLY Eli Lilly and Company	39,000	947.74 million	948.08 million	Optionable
NVO Novo Nordisk A/S	54,400	4.49 billion	4.48 billion	Optionable

AZN, AGN, LLY, and NVO Headlines

Recent News About These Companies

Ritholtz Wealth Management Trims Stock Position in Novo Nordisk A/S (NYSE:NVO)

June 15 at 6:57 AM | marketbeat.com

Wealthcare Advisory Partners LLC Sells 21,139 Shares of Novo Nordisk A/S (NYSE:NVO)

June 15 at 3:56 AM | marketbeat.com

Novo Nordisk A/S (NYSE:NVO) Shares Sold by Yousif Capital Management LLC

June 15 at 3:56 AM | marketbeat.com

Novo Nordisk A/S (NYSE:NVO) Upgraded to "Buy" at Wall Street Zen

June 15 at 3:51 AM | americanbankingnews.com

Dover Advisors LLC Purchases Shares of 7,154 Novo Nordisk A/S (NYSE:NVO)

June 14 at 8:39 AM | marketbeat.com

Azzad Asset Management Inc. ADV Buys New Shares in Novo Nordisk A/S (NYSE:NVO)

June 14 at 6:36 AM | marketbeat.com

Elevation Point Wealth Partners LLC Grows Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

June 14 at 5:53 AM | marketbeat.com

Stanley Laman Group Ltd. Buys New Shares in Novo Nordisk A/S (NYSE:NVO)

June 14 at 5:28 AM | marketbeat.com

Rhumbline Advisers Grows Position in Novo Nordisk A/S (NYSE:NVO)

June 14 at 3:20 AM | marketbeat.com

Novo Nordisk A/S (NYSE:NVO) Upgraded at Wall Street Zen

June 14 at 1:49 AM | marketbeat.com

Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking

June 13 at 6:50 PM | msn.com

Novo Nordisk A/S (NYSE:NVO) Trading Down 1.3% - Time to Sell?

June 13 at 2:22 PM | marketbeat.com

Novo Nordisk plots phase 3 trials for next-gen obesity asset amycretin

June 13 at 1:50 PM | fiercebiotech.com

Novo Nordisk Is Europe's Most Valuable Company—Again. Eli Lilly, Watch Out.

June 13 at 12:58 PM | barrons.com

NVO Stock up on Plans to Advance Obesity Candidate Amycretin

June 13 at 10:11 AM | zacks.com

Novo Nordisk A/S (NYSE:NVO) Shares Sold by Bar Harbor Wealth Management

June 13 at 8:14 AM | marketbeat.com

Smithbridge Asset Management Inc. DE Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

June 13 at 7:36 AM | marketbeat.com

Novo Nordisk A/S (NYSE:NVO) Shares Bought by Union Bancaire Privee UBP SA

June 13 at 5:44 AM | marketbeat.com

Simon Quick Advisors LLC Purchases 4,241 Shares of Novo Nordisk A/S (NYSE:NVO)

June 13 at 5:09 AM | marketbeat.com

Novo Nordisk regains crown as Europe's most valuable company

June 13 at 5:08 AM | reuters.com

Why Novo Nordisk Stock Pumped Higher on Thursday

June 12 at 7:03 PM | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
3 Top-Rated Energy Companies Staging Strong Recoveries
By Nathan Reiff | June 2, 2025
View 3 Top-Rated Energy Companies Staging Strong Recoveries
Best Dollar Store Stock to Buy: Dollar Tree or Dollar General?
By Thomas Hughes | June 5, 2025
View Best Dollar Store Stock to Buy: Dollar Tree or Dollar General?
Why SoundHound Could Be a Short Squeeze in the Making
By Gabriel Osorio-Mazilli | June 2, 2025
View Why SoundHound Could Be a Short Squeeze in the Making
3 Trades Members of Congress Are Making Right Now
By Chris Markoch | May 23, 2025
View 3 Trades Members of Congress Are Making Right Now

AZN, AGN, LLY, and NVO Company Descriptions

Allergan NYSE:AGN

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

AstraZeneca NASDAQ:AZN

$74.42 -0.58 (-0.77%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$74.64 +0.22 (+0.30%)

As of 06/13/2025 07:16 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Eli Lilly and Company NYSE:LLY

$818.56 +6.53 (+0.80%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$819.12 +0.56 (+0.07%)

As of 06/13/2025 07:59 PM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S NYSE:NVO

$79.90 -1.15 (-1.42%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$80.01 +0.11 (+0.14%)

As of 06/13/2025 07:59 PM Eastern

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time